Quantifying Adverse Drug Events : Are Systematic Reviews the Answer?

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2004 Sep 8

PMID 15350149

Citations 8

Authors

Mahyar Etminan

Bruce Carleton

Paula A Rochon

Affiliations

Soon will be listed here.

Abstract

Quantifying adverse drug events (ADEs) is critical to clinicians, consumers and policy makers. Most ADE information comes from large clinical trials. Systematic reviews have become a popular tool in quantifying the efficacy of different therapeutic interventions and ADE data collected in randomised trials may be helpful in quantifying the risk associated with a specific pharmacological agent. However, clinicians who are interested in conducting systematic reviews of ADEs may face many challenges. These challenges are geared towards two main areas: poor quality of ADE reporting in randomised trials and poor indexing of ADEs in medical databases. In this review, we will discuss these challenges in detail using some examples from the literature. Where possible, we also discuss strategies that may overcome these problems. More rigourous standards of reporting ADEs in randomised trials, as well as better indexing of ADE terminology in medical databases, could one day make systematic reviews of ADEs a powerful tool for practising clinicians.

Citing Articles

Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin.

Qureshi R, Mayo-Wilson E, Rittiphairoj T, McAdams-DeMarco M, Guallar E, Li T J Clin Epidemiol. 2021; 143:212-223.

PMID: 34742789 PMC: 9875742. DOI: 10.1016/j.jclinepi.2021.10.024.

Harms in Systematic Reviews Paper 1: An introduction to research on harms.

Qureshi R, Mayo-Wilson E, Li T J Clin Epidemiol. 2021; 143:186-196.

PMID: 34742788 PMC: 9126149. DOI: 10.1016/j.jclinepi.2021.10.023.

Identification and Description of Reliable Evidence for 2016 American Academy of Ophthalmology Preferred Practice Pattern Guidelines for Cataract in the Adult Eye.

Golozar A, Chen Y, Lindsley K, Rouse B, Musch D, Lum F JAMA Ophthalmol. 2018; 136(5):514-523.

PMID: 29800249 PMC: 6145658. DOI: 10.1001/jamaophthalmol.2018.0786.

Adverse Drug Events in Patients with Mental Disorder in an Ambulatory Setting.

Kumar N, Sharma S, Kapoor V Int J Appl Basic Med Res. 2017; 7(2):108-111.

PMID: 28584741 PMC: 5441257. DOI: 10.4103/2229-516X.205822.

Open issues in intelligent personal health record--an updated status report for 2012.

Luo G J Med Syst. 2013; 37(3):9943.

PMID: 23584758 DOI: 10.1007/s10916-013-9943-6.

References

Moher D, Pham B, Jones A, Cook D, Jadad A, Moher M . Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998; 352(9128):609-13. DOI: 10.1016/S0140-6736(98)01085-X. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Huston P, Moher D . Redundancy, disaggregation, and the integrity of medical research. Lancet. 1996; 347(9007):1024-6. DOI: 10.1016/s0140-6736(96)90153-1. View

Frucht S, Greene P, Fahn S . Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord. 2000; 15(4):601-3. DOI: 10.1002/1531-8257(200007)15:4<601::aid-mds1003>3.0.co;2-q. View

Ahmad S . Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003; 18(1):57-60. PMC: 1494803. DOI: 10.1046/j.1525-1497.2003.20130.x. View

Ioannidis J, Cappelleri J, Skolnik P, Lau J, Sacks H . A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996; 156(2):177-88. View

Ernst E, Pittler M . Systematic reviews neglect safety issues. Arch Intern Med. 2001; 161(1):125-6. DOI: 10.1001/archinte.161.1.125-a. View

Tronvik E, Stovner L, Helde G, Sand T, Bovim G . Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2002; 289(1):65-9. DOI: 10.1001/jama.289.1.65. View

Jonsson B . The economic impact of diabetes. Diabetes Care. 1998; 21 Suppl 3:C7-10. DOI: 10.2337/diacare.21.3.c7. View

10.

White T, Arakelian A, Rho J . Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999; 15(5):445-58. DOI: 10.2165/00019053-199915050-00003. View

11.

Derry S, Loke Y, Aronson J . Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol. 2001; 1:7. PMC: 57741. DOI: 10.1186/1471-2288-1-7. View

12.

Bucher H, Guyatt G, Griffith L, Walter S . The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997; 50(6):683-91. DOI: 10.1016/s0895-4356(97)00049-8. View

13.

Ioannidis J, Lau J . Can quality of clinical trials and meta-analyses be quantified?. Lancet. 1998; 352(9128):590-1. DOI: 10.1016/S0140-6736(98)22034-4. View

14.

Etminan M, Levine M, Tomlinson G, Rochon P . Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am J Med. 2002; 112(8):642-6. DOI: 10.1016/s0002-9343(02)01100-2. View

15.

Moher D, Jones A, Lepage L . Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001; 285(15):1992-5. DOI: 10.1001/jama.285.15.1992. View

16.

Etminan M, Samii A, Takkouche B, Rochon P . Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Saf. 2001; 24(11):863-8. DOI: 10.2165/00002018-200124110-00007. View

17.

Ernst F, Grizzle A . Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001; 41(2):192-9. DOI: 10.1016/s1086-5802(16)31229-3. View

18.

Ross S . Drug-related adverse events: a readers' guide to assessing literature reviews and meta-analyses. Arch Intern Med. 2001; 161(8):1041-6. DOI: 10.1001/archinte.161.8.1041. View

19.

Bennett D, Jull A . FDA: untapped source of unpublished trials. Lancet. 2003; 361(9367):1402-3. DOI: 10.1016/S0140-6736(03)13147-9. View

20.

Fletcher A . Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991; 84(6):341-4. PMC: 1293280. DOI: 10.1177/014107689108400612. View